共 146 条
[1]
Coleman RL(2013)Latest research and treatment of advanced-stage epithelial ovarian cancer Nat Rev Clin Oncol 10 211-24
[2]
Monk BJ(2014)Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin Cancer Treat Rev. 40 366-75
[3]
Sood AK(2013)New developments in the treatment of ovarian cancer--future perspectives Ann Oncol 24 x69-76
[4]
Herzog TJ(2012)Cancer prevention by targeting angiogenesis Nat Rev Clin Oncol 9 498-509
[5]
Poveda A(2013)Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer Crit Rev Oncol Hematol 86 161-75
[6]
Ray-Coquard I(2014)Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications Gynecol Oncol 132 496-505
[7]
Romero I(2014)Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: A systematic review J Ovarian Res 7 57-8
[8]
Lopez-Guerrero JA(2014)Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial J Clin Oncol 32 1302-45
[9]
Colombo N(2012)OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2039-96
[10]
Lopez J(2011)A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2484-83